WOA!!! Not sure how to read this.. did a 2nd lab rat exit the sinking ship? Alpine Immune Sciences appoints Zelanna Goldberg as Chief Medical Officer 08:21 ALPN, IOVA Alpine Immune Sciences (APLN) announced the appointment of industry veteran Zelanna Goldberg, M.D., M.A.S. as its Chief Medical Officer. Dr. Goldberg joins Alpine from Iovance Biotherapeutics (IOVA), where she was Senior Vice President, Clinical Science.<--WTF .... In related news Cathie Arkk now is Senior Vice President clinical science at IOVA-!
speaking of ASCO posters, I read the minutes of the Iovance IOVA investor presentation yesterday. they are doing an ASCO presentation over the weekend but a poster Friday morning. according to the temporary CEO, they plan on releasing some additional data to expand on the recent data (whatever that was...I forget...melanoma something) they just released. not sure if the additional data will move the stock, but I bought some shares this morning.
Looks like we did it again Van.- Well you did I just agreed but that's why people like us working together- LifeMD, Inc. (LFMD) Bottoms Up! NasdaqGS - NasdaqGS Real Time Price. Currency in USD 13.46+0.77 (+6.07%)<------------- As of 10:16AM EDT. Market open.
If the additional data is on safety then stk should go up quite a bit. You say Friday morning ! That's tomorrow...
Jesus it is wed. I'm a mess-- I think I know what the new info is it will be survival time because we are still waiting for that. Duration-- But one of their posters is on safety-- and that's big with the FDA<--- Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma. PDF Abstract | ASC0 Annual Meeting, June 4-8, 2021 | Virtual Meeting
Iovance's most advanced study is in advanced melanoma, where its treatment, lifileucel, has shrunk tumors in 25 of 66 treated patients. The company's other program, dubbed LN-145, showed 12 of 27 patients responded to treatment. Both studies have yet to reach a median duration of response after a median of 8.8 months and 7.4 months, respectively, of follow-up. That's undoubtedly the new info because it times out..... Dive Insight: While CAR-T therapies have attracted significant attention with success in treating blood cancers, Iovance is leading the way in developing another type of cell therapy that may prove effective in treating solid tumors. The approach Iovance relies on was first developed in the 1980s and involves patient immune cells called tumor-infiltrating lymphocytes, or TILs. TIL therapy starts with the removal of part of a patient's tumor. TILs present in the sample are then isolated and expanded outside of the body, before being infused back into the patient. The hope is that by using patient immune cells already present in the tumor, TIL-based therapies can better target cancers and bring about longer-term responses. Iovance licensed the technology in 2011 and has ambitions to market the first TIL therapy by 2021, pending an approval from the Food and Drug Administration. The biotech will aim first for an approval in advanced melanoma. Results in that cancer type were from 66 patients with late-stage, unresectable melanoma who had already had three lines of prior treatment on average. Two patients treated with lifileucel achieved a complete response, while 23 experienced a partial one. After nearly nine months of follow-up, the study has yet to yield a median duration of response, which Jefferies analyst Biren Amin called the most encouraging aspect of Iovance's update. Another biotech analyst said doctors have estimated nine to 12 months of response duration would be needed to gain significant traction in melanoma.
A close here and it's Blast Off Time-! Agrify Corporation (AGFY) hits the $10 mark Mutual Funds can now buy. NasdaqCM - NasdaqCM Real Time Price. Currency in USD $10.24+0.37 (+3.7%)<----------
Chart Events DS Bullishpattern detected Drive Shack! Price Crosses Moving Average<------- Performance Outlook 52 week high in striking distance-! Short Term<------- 2W - 6W Mid Term<-------- 6W - 9M Long Term<--- We sold it by then!!!